Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M2,286Revenue $M4.8Net Margin (%)-1,796.4Z-Score-2.6
Enterprise Value $M2,771EPS $-1.7Operating Margin %-911.2F-Score4
P/E(ttm))0Cash Flow Per Share $-1.3Pre-tax Margin (%)-1,333.5Higher ROA y-yY
Price/Book010-y EBITDA Growth Rate %-29.0Quick Ratio18.3Cash flow > EarningsY
Price/Sales2455-y EBITDA Growth Rate %-38.1Current Ratio18.3Lower Leverage y-yN
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-28.4Higher Current Ratio y-yY
Dividend Yield %2.5Insider Buy (3m)1ROE % (ttm)-444.7Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M117ROI % (ttm)-32.8Gross Margin Increase y-yN

Gurus Latest Trades with THRX

Number of guru portfolios checked: 85. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
THRXRichard Perry 2014-12-31 Add1.31%$12.9 - $18.64
($15.01)
$ 19.8632%Add 119.91%4,026,736
THRXRichard Perry 2014-09-30 Add0.19%$17.53 - $30.4
($22.87)
$ 19.86-13%Add 20.69%1,831,099
THRXSeth Klarman 2014-09-30 Reduce-0.28%$17.53 - $30.4
($22.87)
$ 19.86-13%Reduce -2.84%19,815,983
THRXRichard Perry 2014-06-30 Buy 1.2%$21.154 - $30.1
($23.88)
$ 19.86-17%New holding, 1517208 sh.1,517,208
THRXSeth Klarman 2014-06-30 Reduce-0.23%$21.154 - $30.1
($23.88)
$ 19.86-17%Reduce -1.5%20,395,056
THRXSeth Klarman 2014-03-31 Add0.42%$24.31 - $32.63
($29.32)
$ 19.86-32%Add 2.79%20,705,801
THRXSeth Klarman 2013-12-31 Add1.65%$27.19 - $32.81
($29.19)
$ 19.86-32%Add 8.83%20,144,301
THRXJean-Marie Eveillard 2013-12-31 Add0.03%$27.19 - $32.81
($29.19)
$ 19.86-32%Add 23.4%1,509,404
THRXSeth Klarman 2013-09-30 Add2.3%$28.86 - $34.36
($31.06)
$ 19.86-36%Add 11.92%18,510,371
THRXSeth Klarman 2013-06-30 Add2.85%$18.15 - $33.74
($26.83)
$ 19.86-26%Add 22.02%16,538,977
THRXJean-Marie Eveillard 2013-06-30 Add0.08%$18.15 - $33.74
($26.83)
$ 19.86-26%Add 139.14%1,109,620
THRXJean-Marie Eveillard 2012-06-30 Add0.01%$14.11 - $19.04
($16.72)
$ 19.8619%Add 24.23%509,710
THRXSeth Klarman 2012-03-31 Add0.22%$13.21 - $16.28
($13.91)
$ 19.8643%Add 2.3%14,553,800
THRXJean-Marie Eveillard 2012-03-31 Add0.01%$13.21 - $16.28
($13.91)
$ 19.8643%Add 25.59%410,310
THRXSeth Klarman 2011-09-30 Add0.84%$14.05 - $20.04
($16.74)
$ 19.8619%Add 9.76%14,225,961
THRXJulian Robertson 2011-09-30 Sold Out -1.2512%$14.05 - $20.04
($16.74)
$ 19.8619%Sold Out0
THRXJohn Griffin 2011-06-30 Sold Out $17.07 - $23.13
($20)
$ 19.86-1%Sold Out0
THRXJean-Marie Eveillard 2011-06-30 Reduce-0.02%$17.07 - $23.13
($20)
$ 19.86-1%Reduce -33.79%326,710
THRXJean-Marie Eveillard 2011-03-31 Add0.02%$16.91 - $20.77
($18.79)
$ 19.866%Add 51.02%493,410
THRXWilbur Ross 2011-03-31 Sold Out $16.91 - $20.77
($18.79)
$ 19.866%Sold Out0
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

THRX is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
THRX Richard Perry 2014-12-314,026,7363.492.4+119.91%
THRX Jean-Marie Eveillard 2014-12-311,593,6201.380.06
THRX Seth Klarman 2014-12-3119,815,98317.185.5
Premium Most recent portfolio changes are included for Premium Members only!


THRX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
GLAXOSMITHKLINE PLC10% Owner 2015-03-02Buy92,674$1673690-100view
GLAXOSMITHKLINE PLC10% Owner 2014-11-04Buy832,456$12786500-100view
LEE JUNNINGSr. VP, Technical Operations 2014-08-13Sell53,424$22.5-13.07view
Shafer Bradford JSr VP, Gen. Counsel, Secretary 2014-08-12Sell28,156$22.13-11.61view
GLAXOSMITHKLINE PLC10% Owner 2014-08-11Buy172,651$3912270-100view
GLAXOSMITHKLINE PLC10% Owner 2014-05-09Buy317,770$8544840-100view
Shafer Bradford JSr VP, Gen. Counsel, Secretary 2014-03-03Sell65,806$36.73-46.75view
Mammen MathaiSVP, Research & Early Clin Dev 2014-02-14Sell35,000$39.36-50.3view
GLAXOSMITHKLINE PLC10% Owner 2014-02-11Buy342,229$12850700-100view
GLAXOSMITHKLINE PLC10% Owner 2013-10-29Buy130,473$4913610-100view

Press Releases about THRX :

    Quarterly/Annual Reports about THRX:

    News about THRX:

    Articles On GuruFocus.com
    Richard Perry's Fourth-Quarter Transactions Had High Impact on Portfolio Feb 16 2015 
    Seth Klarman Keeps Buying LNG, KERX, PBF And Keeps Selling THRX Dec 05 2014 
    Data Published on Anoro(R) Ellipta(R) Demonstrate Improved Lung Function Compared to Tiotropium Oct 17 2014 
    Theravance, Inc. Appoints Eric d'Esparbes as Senior Vice President and Chief Financial Officer Oct 15 2014 
    Seth Klarman Buys Cheniere Energy, Keryx Biopharmaceuticals, Idenix Pharmaceuticals, Sells BP, Fidel May 15 2014 
    Seth Klarman Buys Micron Technology, Theravance, PBF Energy, Sells BP, AIG, Yamana Gold Nov 13 2013 
    Seth Klarman's Top 5 Second Quarter Holdings Aug 14 2013 
    Top Four from Baupost’s Seth Klarman Jul 18 2013 
    What Can We Earn If We Invest in the Top Five Holdings of the Baupost Group? May 29 2013 
    Weekly CEO Sells Highlight: Texas Roadhouse Inc., Theravance Inc., AmerisourceBergen Corp. and Nuanc May 06 2013 

    More From Our Partners
    Arena Pharmaceuticals' Q4 Loss Wider than Expected - Analyst Blog Mar 3 2015 - ZACKS

    More From Other Websites
    Arena Pharmaceuticals' Q4 Loss Wider than Expected - Analyst Blog Mar 03 2015
    Backed by Genentech alum Dave Goeddel, this company looks like the next biotech IPO Mar 02 2015
    Amgen's Kyprolis Fares Better than Velcade in Study - Analyst Blog Mar 02 2015
    Biogen/Sobi Report Postive Phase III Data on Alprolix - Analyst Blog Mar 02 2015
    Isis Pharmaceuticals Up on Q4 Earnings and Revenues Beat - Analyst Blog Mar 02 2015
    BioMarin's Q4 Loss Narrower than Expected, Gives 2015 View - Analyst Blog Feb 26 2015
    Pharmacyclics (PCYC) Jumps 16.9% on Takeover Rumors - Analyst Blog Feb 26 2015
    Lightning Round: This group goes higher tomorrow Feb 25 2015
    Theravance to Present at the Cowen Healthcare Conference Feb 25 2015
    Iridian exits position in Wyndham Worldwide Corporation Feb 25 2015
    Why Theravance (THRX) Could Be Positioned for a Surge? - Tale of the Tape Feb 25 2015
    Eli Lilly's BIL Filing Delayed, Baricitinib Scores in Phase III - Analyst Blog Feb 24 2015
    THERAVANCE INC Files SEC form 8-K, Other Events Feb 23 2015
    Theravance, Inc. Announces Cash Dividend of $0.25 per Share Payable to Stockholders of Record as of... Feb 23 2015
    Iridian boosts its holdings in W.R. Grace and Company by 25% Feb 20 2015
    Iridian increases its stake in Theravance Feb 19 2015
    Pharmacyclics Misses on Q4 Earnings, Reiterates 2015 View - Analyst Blog Feb 19 2015
    Theravance Reports In Line Loss in Q4, Revenues Increase - Analyst Blog Feb 19 2015
    Theravance reports 4Q loss Feb 19 2015
    Theravance reports 4Q loss Feb 19 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK